The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2025 | Potential treatment options for patients with AML with low expression of ZBTB7A
Vanessa C. Arfelli, PhD, Ludwig-Maximilians-Universität München, Munich, Germany, discusses potential treatment options for patients with low expression of ZBTB7A in normal karyotype acute myeloid leukemia (AML), which is associated with poor outcomes. She implies that therapies targeting ZBTB7A could be beneficial for these patients. She also notes that cells lacking ZBTB7A are more sensitive to venetoclax and proposes investigating combinations of therapies to improve outcomes for these patients. This interview took place at the 19th International Symposium on Acute Leukemias (ISAL XIX) in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
ZBTB7A low expression correlates with a poor outcome in normal karyotype AML. We think the mutated, the TA21 group, it’s not significant, it’s not correlated with a worse outcome, but still we think those patients can benefit from more targeted therapies that have the targets of ZBTB7A as main players there. And the idea is to use this glycolysis inhibitor 2DG at some point to be able to overcome this increasing glycolysis that is providing more energy to the tumor cells...
ZBTB7A low expression correlates with a poor outcome in normal karyotype AML. We think the mutated, the TA21 group, it’s not significant, it’s not correlated with a worse outcome, but still we think those patients can benefit from more targeted therapies that have the targets of ZBTB7A as main players there. And the idea is to use this glycolysis inhibitor 2DG at some point to be able to overcome this increasing glycolysis that is providing more energy to the tumor cells. And we also have seen that in cell lines with loss of ZBTB7A, these cells are more sensitive to venetoclax which is now very well accepted as an alternative for unfit patients. So indeed we think that these patients can benefit from more targeted therapies and not only the standard chemotherapy. So we try to understand which combinations can benefit those patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
